Exploring CBX-12-101: a First-in-Human Study of CBX-12, an AlphalexTM Peptide Drug Conjugate (PDC) in Patients With Advanced or Metastatic Solid Tumors
Time: 9:00 am
day: Conference Day 2
Details:
• AlphalexTM peptides undergo a conformational change in acidic environments facilitating targeted delivery of highly potent anti-cancer therapeutics
• Cybrexa PDCs do not require expression of any cell surface proteins
• Analyzing the activity seen with 3 different schedules in multiple tumor types
